Santaris Pharma

Vector Space Biosciences Files for Registration for Space Launch of Biological CubeSats

Retrieved on: 
Wednesday, August 16, 2023
Research, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Satellite, Science, Biotechnology, Other Technology, Aerospace, Health, Other Science, Manufacturing, Imperial College London, SAB, University College London, Data set, Blockchain, UCL, Human, Radiation, Drug development, University, BCLP, Santaris Pharma, ICL, API, Coronavirus Scientific Advisory Board, Microsoft, UCSD, Oracle, Biology, University of California, San Diego, Vandenberg Space Force Base, Discovery, Protein, CubeSat, City, NASA, Data, Cal Poly, LEO, Ray (optics), McGill University, Artificial intelligence, GCR, Observation, Gel, HZE, Conference, Colloid, Behavior, Mobile phone, Fine chemical, Exolaunch, NVIDIA, AI

Vector Space Biosciences announces it has begun filing for licensing and registration for the design, development and launching of biological CubeSats, enabling biotechnology, pharmaceutical and advanced materials companies to generate unique and powerful datasets to advance the space industry.

Key Points: 
  • Vector Space Biosciences announces it has begun filing for licensing and registration for the design, development and launching of biological CubeSats, enabling biotechnology, pharmaceutical and advanced materials companies to generate unique and powerful datasets to advance the space industry.
  • Customers are invited to pre-register now and during the Vector Space Biosciences talk at Oracle Health Conference on September 20th, 2023.
  • Vector Space Biosciences maintains three divisions: a biosciences lab, AI, Language Modeling & Discovery lab, and hardware lab.
  • Revenue streams result from packages and services offered by the Biological CubeSat Launch Platform (BCLP) along with datasets subscription services.

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors

Retrieved on: 
Tuesday, February 15, 2022
Biochemistry, Patient, MedImmune, Receptor, Board, Max Planck Institute of Biochemistry, Molecular biology, Leadership, Board of directors, GLOBE, Therapy, AstraZeneca, Doctor of Philosophy, Arrival (company), Cancer, Johns Hopkins University, Max Planck Society, Growth, Research, Helmy Eltoukhy, University, Santaris Pharma, Trustee, Drug development, Management, Pharmaceutical industry, Immunocore, Physiology

NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment ofBahija Jallal, Ph.D.to its Board of Directors.

Key Points: 
  • NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment ofBahija Jallal, Ph.D.to its Board of Directors.
  • We are pleased to welcome an executive with Bahijas extensive senior leadership experience to our Board of Directors, saidBing Yao, Chairman, Co-founder and Chief Executive Officer of ArriVent.
  • Bahija is an internationally recognized biopharmaceutical leader, known for her entrepreneurial approach to discovering and delivering innovative biologics products to patients.
  • Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology.

North America miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, Health, Genetics, Science, Research, MicroRNA, RNA transfection, Miravirsen, Mirna, RNA, Degenerative disease, Therapy, CAGR, Cancer, MiR-122, Phase, Genomics, Growth, Hepatitis, Cros, Technology, COVID-19, Research, Santaris Pharma, HCV, Carcinogenesis, Pet, Pharmaceutical industry, Fine chemical

The "North America miRNA Sequencing and Assay Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America miRNA Sequencing and Assay Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • The North America miRNA sequencing and assay market, by product, is segmented into library preparation and consumables.
  • Based on technology, the North America miRNA sequencing and assay market is segmented into sequencing by synthesis, nanopore, and ion semiconductor sequencing.
  • Based on end user, the North America miRNA sequencing and assay market is segmented into research institute, academia, and CROs.

Europe miRNA Sequencing and Assay Market Forecast to 2027: Widening Range of MicroRNA Applications & Rise in Funding for Genomics Research - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Genetics, Science, Pharmaceutical, Research, MicroRNA, QIAGEN, RNA transfection, NGS, Miravirsen, Mirna, RNA, Degenerative disease, Therapy, CAGR, Center for Urban and Regional Analysis, Cancer, MiR-122, Phase, Genomics, Growth, Hepatitis, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Santaris Pharma, HCV, Carcinogenesis, Animal, Vaccine, Pharmaceutical industry

The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The widening application range of microRNAs and rise in funding for genomics research.
  • Therefore, rise in funding of genomic research to identify new molecules to diagnose and treat diseases, and consequent expansion of the range of applications of miRNAs are driving the growth of the miRNA sequencing and assay market in Europe.
  • Hence, the COVID-19 pandemic has been supporting the Europe miRNA sequencing and assay market growth.

Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results

Retrieved on: 
Thursday, March 4, 2021
Life sciences, Biotechnology, Health sciences, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Cancer, Trubion, Santaris Pharma

Management will host a conference call and live webcast at 4:30 p.m.

Key Points: 
  • Management will host a conference call and live webcast at 4:30 p.m.
  • ET on the same day to discuss these results and provide an update on its pipeline programs.
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer.
  • The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases

Retrieved on: 
Monday, November 16, 2020
Life sciences, Biotechnology, Articles, Industries, Santaris Pharma, Draft:Abdul Waseh Basit

OSS, Netherlands, Nov. 16, 2020 /PRNewswire/ -- Lead Pharma , a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, today announced that it has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases.

Key Points: 
  • OSS, Netherlands, Nov. 16, 2020 /PRNewswire/ -- Lead Pharma , a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, today announced that it has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases.
  • In this single target research collaboration Lead Pharma and Roche will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for further development and global commercialization.
  • We are delighted to team up with Roche to pursue this goal", said Frans van den Berg, Chief Executive Officer of Lead Pharma.
  • Lead Pharma is a pharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of immune diseases and cancer.

Applied Therapeutics Reports Fourth Quarter and Year-end 2019 Financial Results

Retrieved on: 
Friday, March 13, 2020
Companies, Trubion, Economy of the United States, Santaris Pharma

NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2019.

Key Points: 
  • NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2019.
  • This past year was a transformative time for Applied Therapeutics.
  • In November 2019, we presented clinical data on AT-001 at AHA 2019 in Philadelphia, Pennsylvania.
  • Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.

Genevant Sciences to Present at Biotech Showcase 2020

Retrieved on: 
Monday, January 6, 2020
Biotechnology, Pharmaceutical, Genetics, Health, Santaris Pharma

Genevant Sciences, an emerging biopharmaceutical company developing a diverse pipeline of innovative RNA therapeutics that exploit industry-leading nucleic acid delivery capabilities, today announced that Bo Rode Hansen, PhD, President and Chief Executive Officer of Genevant Sciences, Inc., will present on Tuesday, January 14, 2020, at 3:15 PM PT at Biotech Showcase 2020.

Key Points: 
  • Genevant Sciences, an emerging biopharmaceutical company developing a diverse pipeline of innovative RNA therapeutics that exploit industry-leading nucleic acid delivery capabilities, today announced that Bo Rode Hansen, PhD, President and Chief Executive Officer of Genevant Sciences, Inc., will present on Tuesday, January 14, 2020, at 3:15 PM PT at Biotech Showcase 2020.
  • The presentation will be made in Franciscan C on the Ballroom level of the Hilton San Francisco Union Square.
  • Genevant Sciences is an emerging biopharmaceutical company developing a diverse pipeline of innovative RNA therapeutics that exploit industry-leading nucleic acid delivery capabilities.
  • Genevant is committed to transforming the future of human health.

Step Pharma Appoints Seasoned Drug Developer Dr. Andrew Parker as Chief Executive Officer

Retrieved on: 
Friday, September 6, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Pharma, Santaris Pharma

Step Pharma, a biotech company developing novel drugs for autoimmune diseases, today announced the appointment of Andrew Parker, Ph.D., as Chief Executive Officer and member of the Supervisory Board.

Key Points: 
  • Step Pharma, a biotech company developing novel drugs for autoimmune diseases, today announced the appointment of Andrew Parker, Ph.D., as Chief Executive Officer and member of the Supervisory Board.
  • Dr. Parker joins Step Pharma with more than 20 years experience in various research and development roles at international pharmaceutical, biotech and start-up companies.
  • View the full release here: https://www.businesswire.com/news/home/20190905005630/en/
    Dr Andrew Parker joins Step Pharma as CEO (Photo: Business Wire)
    Andy has a proven track record in developing novel drugs both within large pharma as well as biotech.
  • Most recently, Dr. Parker was Executive Vice President and Chief Science Officer of Zealand Pharma, a developer of peptide-based medicines to treat rare diseases in the gastrointestinal and metabolic areas.

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

Retrieved on: 
Wednesday, January 23, 2019
Health, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Research, Science, Life sciences, Articles, Biotechnology, Industries, Pharmaceuticals policy, Science and technology in the People's Republic of China, Santaris Pharma

BridgeBio Pharma , a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million.

Key Points: 
  • BridgeBio Pharma , a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million.
  • The financing will be used to support BridgeBio Pharma's existing drug research and development programs and expand its efforts to rapidly develop medicines for patients with unmet needs.
  • We are privileged to be working with investors who believe in our goal of creating medicines for patients with genetic disease.
  • BridgeBio Pharma was formed in 2015 by a team of drug research and development veterans from both the biotech industry and academia.